CIRCULATE Japan Summary
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent metastatic gastroesophageal cancers
Read More
-
Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers with Pathologic Complete Response
Read More
-
Feasibility and Dynamics of Preoperative Circulating Tumor DNA in Gastroesophageal Cancer Patients Receiving Preoperative Treatment
Read More
-
Molecular Residual Disease and Efficacy of Adjuvant Chemotherapy in Patients with Colorectal Cancer
Read More
-
Observed Scenarios of ctDNA Dynamics During Adjuvant Therapy
Watch Video
-
Using ctDNA to Guide the Management of GI Cancers
Watch Video
-
Webinar: Latest data using ctDNA to assess breast cancer recurrence risk and treatment response
Watch Video
-
Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center
Read More
-
Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib
Read More
-
Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer
Read More
-
Compassionate Care Application
Read More
-
Oncology Patient Signatera Requisition Form
Read More
-
Asco 2022 Monitoring Efficacy of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma
Read More
-
Webinar: ctDNA as a predictive biomarker for immunotherapy response
Watch Video
-
ASCO GU 2022 Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring
Read More
-
Optimizing the management of patients with solid tumors using a tumor-informed approach
Watch Video
-
Signatera Breast Cancer Data Sheet
Read More
-
Serial postoperative ctDNA monitoring of breast cancer recurrence
Read More
-
Comparison of the predictive and prognostic significance of circulating tumor DNA
Read More
-
Loading More...
